Fracture risk following intermission of osteoporosis therapy

被引：0
|
作者：
E.M. Dennison
C. Cooper
J.A. Kanis
O. Bruyère
S. Silverman
E. McCloskey
B. Abrahamsen
D. Prieto-Alhambra
S. Ferrari
机构：
[1] University of Southampton,MRC Lifecourse Epidemiology Unit
[2] University of Oxford,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
[3] University of Sheffield,Centre for Metabolic Bone Diseases, University of Sheffield Medical School
[4] Australian Catholic University,Mary McKillop Health Institute
[5] University of Liège,World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics
[6] Cedars-Sinai/UCLA Medical Center and OMC Clinical Research Center,Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, The Mellanby Centre For Bone Research
[7] University of Sheffield,Department of Medicine
[8] Holbaek Hospital,OPEN, Institute of Clinical Research
[9] University of Southern Denmark,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
[10] University of Oxford,GREMPAL Research Group, Idiap Jordi Gol and CIBERFes
[11] Universitat Autonoma de Barcelona and Instituto de Salud Carlos III,Division of Bone Disease, Faculty of Medicine
[12] Geneva University Hospital,undefined
来源：
Osteoporosis International | 2019年 / 30卷
关键词：
Atypical fracture; Bisphosphonates; Denosumab; Drug holiday;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1733 / 1743
页数：10
相关论文
共 50 条
  • [31] Influence of specific osteoporosis drugs on fracture healing
    Hesse, Eric
    Neuerburg, Carl
    Kammerlander, Christian
    Stumpf, Ulla
    Stange, Richard
    Boecker, Wolfgang
    UNFALLCHIRURG, 2019, 122 (07): : 506 - 511
  • [32] Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications
    Nyandege, Abner N.
    Slattum, Patricia W.
    Harpe, Spencer E.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 437 - 447
  • [33] Treating osteoporosis in patients with atypical femoral fracture
    Adler, Robert A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (12) : 1711 - 1715
  • [34] Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study
    Wu, Y. -C.
    Chen, S.
    Wu, P. -L.
    Tsou, H. -K.
    Wei, J. C. -C.
    JOURNAL OF INTERNAL MEDICINE, 2022, 291 (03) : 384 - 385
  • [35] Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
    Leder, Benjamin Z.
    Mitlak, Bruce
    Hu, Ming-Yi
    Hattersley, Gary
    Bockman, Richard S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03) : 938 - 943
  • [36] Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024
    De Mattia, G.
    Maffi, M.
    Mazzantini, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (07) : 1311 - 1316
  • [37] Osteoporosis, the risk of vertebral fracture, and periodontal disease in an elderly group in Mexico City
    Moedano, Diana E.
    Irigoyen, Maria E.
    Borges-Yanez, Aida
    Flores-Sanchez, Ismael
    Rotter, Ricardo C.
    GERODONTOLOGY, 2011, 28 (01) : 19 - 27
  • [38] Risk of jaw osteonecrosis and atypical femoral fracture: how to inform patients with osteoporosis?
    Popp, Albrecht W.
    THERAPEUTISCHE UMSCHAU, 2025, 82 (01) : 35 - 38
  • [39] Safety of In-hospital Parenteral Antiosteoporosis Therapy Following a Hip Fracture: A Retrospective Cohort
    Abu-Jwead, Alaa
    Fisher, David L.
    Goldabart, Adi
    Yoel, Uri
    Press, Yan
    Tsur, Anat
    Fraenkel, Merav
    Baraf, Lior
    JOURNAL OF THE ENDOCRINE SOCIETY, 2024, 8 (11)
  • [40] Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada
    Leslie, William D.
    Lix, Lisa M.
    Binkley, Neil
    ARCHIVES OF OSTEOPOROSIS, 2020, 15 (01)
12345